Home Cart Sign in  
Chemical Structure| 209860-87-7 Chemical Structure| 209860-87-7

Structure of Tafluprost
CAS No.: 209860-87-7

Chemical Structure| 209860-87-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Tafluprost is an anti-glaucoma prostaglandin (PG) analog.

Synonyms: AFP-168; MK2452; AFP-168, AFP-168, AFP-168, MK-2452, MK2452, MK 2452, Saflutan, Taflotan, Tapros, Zioptan

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Tafluprost

CAS No. :209860-87-7
Formula : C25H34F2O5
M.W : 452.53
SMILES Code : O=C(OC(C)C)CCC/C=C\C[C@@H]1[C@@H](/C=C/C(F)(F)COC2=CC=CC=C2)[C@H](O)C[C@@H]1O
Synonyms :
AFP-168; MK2452; AFP-168, AFP-168, AFP-168, MK-2452, MK2452, MK 2452, Saflutan, Taflotan, Tapros, Zioptan
MDL No. :MFCD08062150
InChI Key :WSNODXPBBALQOF-VEJSHDCNSA-N
Pubchem ID :9868491

Safety of Tafluprost

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Tafluprost

GPCR

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01434888 Healthy Volunteers Phase 1 Completed - Finland ... More >> Kuopio University Hospital Eye Clinic Kuopio, Finland, 70200 Less <<
NCT01654484 Glaucoma and Ocular Hypertensi... More >>on Less << Phase 1 Phase 2 Completed - United States, California ... More >> Santen Investigational Site Newport Beach, California, United States, 92663 United States, Florida Santen Investigational Site Deerfield Beach, Florida, United States, 33064 Santen Investigational Site Largo, Florida, United States, 33773 United States, Georgia Santen Investigational Site Morrow, Georgia, United States, 30260 Santen Investigational Site Roswell, Georgia, United States, 30076 United States, New York Santen Investigational Site Rochester, New York, United States, 14618 United States, Ohio Santen Investigational Site Cleveland, Ohio, United States, 44115 United States, Texas Santen Investigational Site Austin, Texas, United States, 78731 Santen Investigational Site Fort Worth, Texas, United States, 76102 Santen Investigational Site San Antonio, Texas, United States, 78240 Less <<
NCT01927406 Thyroid Eye Disease ... More >> Ocular Hypertension Glaucoma Less << Phase 4 Withdrawn(Funding source unava... More >>ilable) Less << December 2016 United States, California ... More >> Stanford Hospital and Clinics Stanford, California, United States, 94304 Less <<
NCT03595865 Glaucoma; Drugs Not Applicable Not yet recruiting June 1, 2020 -
NCT01263444 Glaucoma Ocul... More >>ar Hypertension Less << Phase 4 Completed - -
NCT01263444 - Completed - -
NCT01433900 Glaucoma Phase 3 Unknown June 2014 Italy ... More >> San Paolo Hospital Recruiting Milano, Italy, 20142 Principal Investigator: Luca Rossetti, MD          Principal Investigator: Paolo Fogagnolo, MD Less <<
NCT01263535 Glaucoma Phase 4 Terminated - Switzerland ... More >> University Hospital Geneva Geneva, Switzerland, 1211 Less <<
NCT03292796 Open Angle Glaucoma and Catara... More >>ct Less << Phase 2 Recruiting December 31, 2018 United Kingdom ... More >> Norfolk & Norwich University Hospitals NHS Foundation Trust Recruiting Norwich, Norfolk, United Kingdom, NR4 7UY Contact: Dawson Julie, Mrs    +44 1603 286611    julie.dawson@nnuh.nhs.uk    Contact: Andrew Holmes, Mr    +44 1603 287376    andrew.holmes@nnuh.nhs.uk    Principal Investigator: Nuwan Niyadurupola, Consultant          Sub-Investigator: David Broadway, Professor          Sub-Investigator: Tom Eke, Consultant Less <<
NCT01026831 - Completed - -
NCT01026831 Open-angle Glaucoma ... More >> Ocular Hypertension Less << Phase 3 Completed - -
NCT01087671 Ocular Hypertension ... More >> Open-Angle Glaucoma Less << Phase 3 Completed - -
NCT01342081 - Completed - -
NCT01342081 Open Angle Glaucoma ... More >> Ocular Hypertension Less << Phase 3 Completed - Japan ... More >> Santen study sites Osaka, Japan Less <<
NCT01254604 Glaucoma Ocul... More >>ar Hypertension Less << Phase 3 Completed - -
NCT00596791 Ocular Hypertension ... More >> Open-Angle Glaucoma Less << Phase 3 Completed - Finland ... More >> Finn-Medi Research Oy Tampere, Finland, 33520 Less <<
NCT02471105 Ocular Hypertension ... More >> Glaucoma Less << Phase 4 Unknown December 2017 Austria ... More >> Hommer Ophthalmology Institute Recruiting Vienna, Austria Contact: Anton Hommer          Belgium UZ Leuven Recruiting Leuven, Vlaams Brabant, Belgium, 3000 Contact: Ingeborg Stalmans, Phd    003216332372    ingborg.stalmans@uzleuven.be    Contact: Sien Boons, Optometrist    003216340391    sien.boons@uzleuven.be    Italy San Paolo Hospital Not yet recruiting Milan, Italy Contact: Luca Rossetti          Bietti Foundation Not yet recruiting Rome, Italy Contact: francesco Oddone          Switzerland Clinical Research Centre Momorial A. de Rotschild Not yet recruiting Geneve, Switzerland Contact: Gordana Megevand          United Kingdom Gloucestershire Hospitals NHS Foundation Trust Not yet recruiting Gloucestershire, United Kingdom Contact: Andrew McNaught          Western Eye Hospital Not yet recruiting London, United Kingdom Contact: Francesca Cordeiro Less <<
NCT01254604 - Completed - -
NCT00918346 Open-Angle Glaucoma ... More >> Ocular Hypertension Less << Phase 3 Completed - Finland ... More >> Oulu University Hospital Oulu, Finland, 90029 Germany Ulrich Richter's surgery Regensburg, Germany, 93059 Praxis Dr. Hamacher Starnberg, Germany, 82319 Less <<
NCT00918346 - Completed - -
NCT00966940 Glaucoma Phase 4 Completed - -
NCT02802137 Glaucoma Ocul... More >>ar Surface Disease Less << Phase 4 Completed - -
NCT03204487 Glaucoma, Open-Angle ... More >> Ocular Hypertension Less << Phase 4 Completed - Austria ... More >> Ordination Dr. Hommer Vienna, Austria, 1080 Less <<
NCT00966940 - Completed - -
NCT01979913 Primary Open Angle Glaucoma ... More >> Ocular Hypertension Less << Phase 4 Completed - Austria ... More >> Ordination Dr. Hommer Vienna, Austria, 1080 Less <<
NCT01369771 Ocular Hypertension ... More >> Open-Angle Glaucoma Less << Phase 4 Completed - Finland ... More >> FinnMedi Oy, Clinical Trial Center Tampere, Pirkanmaa district, Finland, 33520 Less <<
NCT01292460 Ocular Hypertension ... More >> Open-angle Glaucoma Less << Phase 3 Completed - Finland ... More >> Eye clinic, University Hospital of Kuopio Kuopio, Finland, 70210 Eye Clinic, University Hospital of Oulu Oulu, Finland, 90029 OYS Less <<
NCT02102750 Glaucoma Ocul... More >>ar Hypertension Less << Phase 1 Completed - United States, Pennsylvania ... More >> Childrens Hospital of Philadelphia (CHOP) Philadelphia, Pennsylvania, United States, 19104 United Kingdom Moorfields Eye Hospital London, United Kingdom, EC1V 2PD Less <<
NCT01306461 Ocular Hypertension ... More >> Open-angle Glaucoma Less << Phase 3 Completed - Hungary ... More >> Debrecen, Hungary Less <<
NCT03104621 Primary Open-angle Glaucoma Phase 4 Completed - -
NCT03612817 Glaucoma, Open-Angle Phase 4 Completed - Greece ... More >> 1st University Department of Ophthalmology Thessaloníki, Makedonia, Greece, 54636 Less <<
NCT01162603 Primary Open Angle Glaucoma ... More >> Ocular Hypertension Less << Phase 4 Completed - Greece ... More >> Glaucoma Unit, 1st University Department of Ophthalmology, Aristotle University, AHEPA Hospital Thessaloniki, Greece, 54636 Italy USVD "Centro per lo studio del glaucoma" Spedali civili di Brescia Brescia, Italy, 25123 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.21mL

0.44mL

0.22mL

11.05mL

2.21mL

1.10mL

22.10mL

4.42mL

2.21mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories